10-Q quarterly report · filed Nov 4, 2026

Viridian Therapeutics, Inc.\DE (VRDN) Q3 2026 10-Q Quarterly Report

Short answer

Viridian Therapeutics, Inc.\DE (VRDN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $26M (down 63.5% year over year) with net income of −$101M.

Q3 2026 key financials · XBRL

Revenue
$26M
−63.5% YoY · +8967.6% QoQ
Net income
−$101M
−192.5% YoY · +20.4% QoQ
Operating margin
-401.8%

Source: XBRL data from the Viridian Therapeutics, Inc.\DE (VRDN) Q3 2026 10-Q on SEC EDGAR. USD.

Viridian Therapeutics, Inc.\DE Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $24.7M, versus $70.0M license revenue in Q3 2025, driven by new veligrotug sales
  • Net loss $101.2M vs $34.6M YoY, with cost of revenues $1.5M and SG&A $57.6M
  • TED R&D largest at $23.9M, down $31.3M YoY; other research programs increased $5.9M to $7.2M
  • Cash, equivalents and marketable securities $955.2M; operating cash use $317.8M through nine months
  • Outlook: elegrobart BLA expected Q1 2027; macroeconomic uncertainty, tariffs, inflation and supply-chain risks 񟿿

Risk Factors

  • Newly emphasized regulatory risk: BIOSECURE Act enacted December 2025, potentially restricting WuXi services and U.S. government contracting
  • Most material update: FDA disruption risk from federal shutdowns and workforce reductions, threatening BLA reviews and inspections
  • Operational risk: Single-sourced manufacturing with WuXi for veligrotug and product candidates, exposing supply continuity
  • Competitive risk: More than 20 FcRn indications in development, increasing potential competition for the pipeline
  • Financial risk: $250.0 million 1.75% convertible senior notes due 2032, requiring future cash servicing or refinancing

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Viridian Therapeutics, Inc.\DE quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.